Brief: Immunovia In Q4 Will Initiate A Large Clinical Validation Study
29/04/2024 08:37
April 29 (Reuters) - Immunovia AB (publ) IMMNOV.ST :
* WILL PARTNER WITH LEADING PANCREATIC CANCER RESEARCHERS ON
ADDITIONAL CLINICAL STUDIES STARTING IN EARLY 2025
* IN SECOND AND THIRD QUARTERS, WE WILL PERFORM SEVERAL
ANALYTICAL
VALIDATION STEPS TO VERIFY ACCURACY AND REPRODUCIBILITY OF
PROTEIN ASSAYS
* IN Q4, WE WILL INITIATE A LARGE CLINICAL VALIDATION STUDY
* COMPANY IS CURRENTLY FUNDED INTO Q4 OF 2024
* NEGOTIATING TO REDUCE OR ELIMINATE LONG-TERM FINANCIAL
COMMITMENTS LINKED TO NOW-DISCONTINUED IMMRAY™ PAN-CAN-D PRODUCT
Source text for Eikon: ID:nWkr6s8Zmw
Further company coverage: IMMNOV.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))